R-Pharm

R-Pharm licenses Merck hepatitis C drug

Friday, July 6, 2012

The Russian pharmaceutical company R-Pharm—headed by the Ministry of Industry and Trade of the Russian Federation—entered into a licensing agreement with MSD (Merck) for rights to a novel investigational, hepatitis C once-daily protease inhibitor, narlaprevir. 

[Read More]